(Q36512521)

14 August 2017

1 reference

title

Role of the microenvironment in multiple myeloma bone disease (English)

1 reference

14 August 2017

1 reference

Alissa Huston

1

1 reference

14 August 2017

G David Roodman

series ordinal

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

2

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

371-378

1 reference

Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

Pathogenesis of myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

Myeloma cells (5TMM) and their interactions with the marrow microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

Clinical evaluation of onset of analgesia using intravenous pamidronate in metastatic bone pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.3.371

21 January 2018

Identifiers

DOI

10.2217/14796694.2.3.371

1 reference

14 August 2017

1 reference